Grants per year
Personal profile
Research Interests
My clinical interests include Parkinson’s disease and atypical parkinsonian syndromes, tremors, dystonia, Huntington’s disease, Wilson’s disease, tic disorders, psychogenic movement disorders and gait disorders. I perform botulinum toxin injections, assessments for DBS (deep-brain stimulation), and I am involved in several clinical trials for Parkinson’s disease and other movement disorders. I am interested in the importance of a holistic approach to health and wellness and have conducted studies on complementary and integrative medicine as well. I am the director of the multi-disciplinary Huntington's disease clinic and Wilson's disease clinic. I am also the program director for the neurology residency program.
Training Experience
| 2010 | Internship, Rush University Medical Center |
| 2013 | Residency, Massachusetts General Hospital/Brigham & Women’s Hospital (Harvard Medical School) |
| 2014 | Fellowship, Northwestern University, Feinberg School of Medicine |
Education/Academic qualification
MD, Medicine, Rush University
… → 2009
Research interests keywords
- Botulinum Toxin
- Huntington’s Disease
- Integrative Medicine
- Movement Disorders
- Neurology
- Parkinson’s Disease
Fingerprint
Dive into the research topics where Danny Bega is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #WE45491: Frequency of Selected Single Nucleotide Polymorphisms in Phase With The Mutant and Wild-Type HTT Alleles in Huntington Disease Gene Expansion Carriers
Bega, D. (PD/PI)
12/11/24 → 12/11/25
Project: Research project
-
Parkinson's Foundation 2025-2026 Global Care Network Award - Center of Excellence
Simuni, T. (PD/PI) & Bega, D. (Other)
12/1/24 → 11/30/26
Project: Research project
-
Enroll-HD Study Site Agreement, dated Apr 23, 2015 (RecID A-9045) – Enroll-HD Study Price Increase
Bega, D. (PD/PI)
7/1/23 → 6/30/28
Project: Research project
-
(OE) Prot# BN42489: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Biomakers, and Efficacy of Tominersen in Individuals with Prodromal and Early Manifest Hungtington's Disease
Bega, D. (PD/PI)
INC Research, LLC, Genentech, Inc
3/6/23 → 11/30/26
Project: Research project
-
Prot# 718-CNP-202: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Parkinson's Disease Cognitive Impairment
Bega, D. (PD/PI)
Parexel, Sage Therapeutics, Inc.
2/28/23 → 2/28/26
Project: Research project
-
Caffeine Use in Huntington's Disease: A Single Center Survey
Adrissi, J., Brooker, S. M., Mcbride, A., Larson, D. N., Gausche, E. D. & Bega, D., 2024, In: Tremor and other hyperkinetic movements (New York, N.Y.). 14, p. 52 1 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials
the AL-108-231 Investigators, the Tauros MRI Investigators, the PASSPORT Study Group, the DESCRIBE-PSP Group, Aug 2024, In: Movement Disorders. 39, 8, p. 1329-1342 14 p.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations -
The Impact of Drug Interactions on the Results of DAT-SPECT Imaging in a Specialty Movement Disorders Practice: A Retrospective Analysis of Outcomes
Kang, I. H. & Bega, D., Sep 1 2024, In: Neurodegenerative Diseases. 24, 2, p. 91-95 5 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Advance Care Planning and Health-Related Quality of Life in Huntington Disease: Results from a Multicenter National Study
Sokol, L. L., Troost, J. P., Bega, D., Kluger, B. M., Prigerson, H. G., Nance, M., Frank, S., Perlmutter, J. S., Dayalu, P., Cella, D. & Carlozzi, N. E., Mar 1 2023, In: Palliative Medicine Reports. 4, 1, p. 79-88 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (Nature Medicine, (2021), 27, 8, (1451-1457), 10.1038/s41591-021-01455-x)
PASSPORT Study Group, Nov 2023, In: Nature Medicine. 29, 11, p. 2955-2956 2 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access
Datasets
-
Supplementary Material for: The Impact of Drug Interactions on the results of DAT-SPECT Imaging in a Specialty Movement Disorders Practice: A Retrospective Analysis of Outcomes
Kang, I. H. (Contributor) & Bega, D. (Contributor), Karger Publishers, 2024
DOI: 10.6084/m9.figshare.26130010.v1, https://karger.figshare.com/articles/dataset/Supplementary_Material_for_The_Impact_of_Drug_Interactions_on_the_results_of_DAT-SPECT_Imaging_in_a_Specialty_Movement_Disorders_Practice_A_Retrospective_Analysis_of_Outcomes/26130010/1
Dataset
-
Disparities in Palliative Care Utilization Among Hospitalized People With Huntington Disease: A National Cross-Sectional Study
Sokol, L. L. (Creator), Bega, D. (Creator), Yeh, C. (Creator), Kluger, B. M. (Creator) & Lum, H. D. (Creator), SAGE Journals, 2021
DOI: 10.25384/sage.c.5525847, https://sage.figshare.com/collections/Disparities_in_Palliative_Care_Utilization_Among_Hospitalized_People_With_Huntington_Disease_A_National_Cross-Sectional_Study/5525847
Dataset